JPRN-jRCTs031190021已完成未知
Tofogliflozin And Empagliflozin Cross-over TrIal to Compare the effects on NT-proBNP in patients with type 2 diabeteS (TACTICS)
Yamada Yoshihiko0 个研究点目标入组 56 人开始时间: 2019年5月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 56
研究概览
简要总结
In the blood NT-proBNP value and the main laboratory parameters, no significant difference was found the effect between the drugs. The value of eGFR during the tofogliflozin administration period was significantly higher than the value during the empagliflozin administration period. For some parameters, a significant difference was found between the treatment groups in the comparison of the rate of change before and after administration of the study drug.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 75age old（—）
- 性别
- All
入选标准
- •1.Type 2 diabetes mellitus.
- •2.HbA1c is 6.5-9.9%. (measured within 90 days before consent)
- •3.Men or woman, aged 20-74years.
- •4.Patients who provide written consent to participate in the trial of their own free will.
排除标准
- •1.Type 1 diabetes mellitus.
- •2.Patients using insulin.
- •3.Patients using SGLT2 inhibitors within 4 weeks before consent.
- •4.BMI is less than 18.5 kg/m2 within 90 days before consent.
- •5.History of cerebral infarction.
- •6.Serious hepatic dysfunction or hepatic biomarker is more than 2.5 times upper limit of normal(measured within 90 days before consent).
- •7.Serious renal dysfunction or eGFR is less than 30 mL /min/1.73 m2(measured within 90 days before consent).
- •8.Heart failure (NYHA III or more).
- •9.Severe ketosis, diabetic coma or precoma.
- •10.Sever infection, within one week before or after the surgery, sever injury.
- •11.History of hypersensitivity to any of the ingredients of the study drug.
- •12.Pregnant women, women suspected of being pregnant.
- •13.Patients who are ineligible in the opinion of the investigator.
研究者
相似试验
已完成
不适用
Two-way crossover comparison of tofogliflozin and canagliflozin using continuous glucose monitoring.Type 2 diabetesJPRN-UMIN000024969Kitasato University School of Pharmacy20
招募中
Unknown
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26
招募中
不适用
Bioequivalence study of Empagliflozin 25 mg tablet in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actoverco. Empagliflozin 25 mg tablet with brand Jardiance 25 mg tablet Boehringer..IRCT20180620040164N19Actover Pharmaceutical Co.24
招募中
不适用
In-vivo Bioequivalence Test of Empagliflozin tablets with brand drug (JARDIANCE® 25 mg, Boehringer Ingelheim , Germany)Bio equivalence test.IRCT20200105046010N49Pars Darou Pharm. Co.24